The WFH Gene Therapy Round Table Series

The WFH Gene Therapy Round Table (GTRT) series began in 2018. Bringing together WFH national member organizations (NMOs), patient advocates, health care professionals, regulators and industry, this annual multi-stakeholder meeting is an up-to-date dialogue on the current global developments and expected challenges related to gene therapy for hemophilia. The 3rd WFH GTRT will take place in March 2020 in Montreal, Canada.

Participating

This is an invitation only meeting. Approximately 60 participants are invited annually from the international bleeding disorders community, including key scientific experts, regulators, payors, patient leaders and advocates, health care professionals, scientists, and industry representatives.

Objectives

The objectives of this series are to better understand the challenges related to the development of gene therapy for people with hemophilia around the world. Key challenges and discussions centre around global access to gene therapy, regulatory and financial challenges, the unknowns of gene therapy and long-term follow-up of safety and efficacy. Multi-stakeholder and global perspectives are considered.

The key challenges identified in the 1st WFH GTRT have been published and the programs of the 1st and 2nd WFH GTRT are available.

Gene Therapy Round Table Program Committee

Co-Chairs
Glenn Pierce, U.S.A.
John Pasi, U.K.

Members
A revolving committee of approximately eight health care professionals, and people with a bleeding disorder and/or caregivers make up the program committee.